Ladybon (Tibolone)

Tibolone binds to estrogen, progesterone and androgen receptors, providing a balanced hormonal effect. This mixed activity reduces vasomotor symptoms, supports endometrial stability, and promotes bone formation while limiting bone resorption.

The dosage of Ladybon is determined by the prescribing clinician based on the individual’s health status, severity of symptoms, and treatment goals. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Ladybon is contraindicated in pregnancy and breastfeeding. Tibolone can affect fetal development and is not recommended for nursing mothers because it may pass into breast milk and influence the infant.

To order Ladybon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike traditional estrogen‑only or combined estrogen‑progestogen therapies, tibolone offers estrogenic, progestogenic and androgenic actions in a single molecule. This can provide broader symptom control and bone benefits, but the safety profile differs, especially regarding thrombotic and cancer risks, which should be weighed against alternative options.

Ladybon should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and excessive heat to maintain its stability and potency.

Ladybon is taken orally, usually as a tablet, with or without food as directed by the prescriber. The exact administration schedule is individualized, and patients should follow the dosing instructions provided by their healthcare professional.

Serious risks include venous thromboembolism, stroke, liver dysfunction, and an increased potential for hormone‑dependent cancers such as breast or endometrial cancer. Patients should be monitored regularly for signs of these conditions, and therapy should be discontinued if serious adverse events occur.

Ladybon should not be used by women who are pregnant, breastfeeding, have a history of hormone‑sensitive cancers, active liver disease, unexplained vaginal bleeding, or who have experienced thromboembolic events. Contraindications also include known hypersensitivity to tibolone or any excipients in the formulation.